The circular RNome of primary breast cancer.


Journal

Genome research
ISSN: 1549-5469
Titre abrégé: Genome Res
Pays: United States
ID NLM: 9518021

Informations de publication

Date de publication:
03 2019
Historique:
received: 05 04 2018
accepted: 23 01 2019
pubmed: 30 1 2019
medline: 14 6 2019
entrez: 30 1 2019
Statut: ppublish

Résumé

Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely on unmapped reads or known splice junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of the circRNAs that match exon boundaries of the same gene, 668 showed a poor or even negative (

Identifiants

pubmed: 30692147
pii: gr.238121.118
doi: 10.1101/gr.238121.118
pmc: PMC6396421
doi:

Substances chimiques

Biomarkers, Tumor 0
CNOT2 protein, human 0
Carrier Proteins 0
RERE protein, human 0
RNA, Circular 0
Repressor Proteins 0
RNA 63231-63-0
CREB-Binding Protein EC 2.3.1.48
CREBBP protein, human EC 2.3.1.48

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

356-366

Subventions

Organisme : NCI NIH HHS
ID : P50 CA168504
Pays : United States
Organisme : Wellcome Trust
ID : WT100183MA
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : Wellcome Trust
ID : 077012/Z/05/Z
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 Smid et al.; Published by Cold Spring Harbor Laboratory Press.

Références

Clin Cancer Res. 2005 Oct 15;11(20):7311-21
pubmed: 16243802
Cancer Res. 2007 Apr 1;67(7):3441-9
pubmed: 17409455
Int J Cancer. 2008 Mar 15;122(6):1324-32
pubmed: 17999412
Cancer Res. 2008 May 1;68(9):3108-14
pubmed: 18451135
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13021-6
pubmed: 18755890
Genome Res. 2009 Jul;19(7):1316-23
pubmed: 19498102
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Cell. 2012 Jan 20;148(1-2):29-32
pubmed: 22265399
PLoS One. 2012;7(2):e30733
pubmed: 22319583
Cell. 2012 May 25;149(5):979-93
pubmed: 22608084
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747
Science. 2012 Dec 21;338(6114):1587-93
pubmed: 23258890
Science. 2012 Dec 21;338(6114):1593-9
pubmed: 23258891
Nature. 2013 Mar 21;495(7441):384-8
pubmed: 23446346
Nature. 2013 Mar 21;495(7441):333-8
pubmed: 23446348
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
PLoS Genet. 2013;9(9):e1003777
pubmed: 24039610
Genome Biol. 2014 Jul 29;15(7):409
pubmed: 25070500
Mol Oncol. 2014 Dec;8(8):1679-89
pubmed: 25081647
Cell. 2014 Sep 25;159(1):134-147
pubmed: 25242744
Clin Chem. 2015 Jan;61(1):221-30
pubmed: 25376581
RNA. 2015 Feb;21(2):172-9
pubmed: 25449546
Cell Rep. 2015 Jan 13;10(2):170-7
pubmed: 25558066
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
Bioinformatics. 2015 Jun 15;31(12):2032-4
pubmed: 25697820
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Cell Res. 2015 Aug;25(8):981-4
pubmed: 26138677
Genome Biol. 2015 Aug 08;16:160
pubmed: 26253137
Cancer Cell Int. 2015 Oct 29;15:103
pubmed: 26516313
BMC Cancer. 2015 Nov 09;15:877
pubmed: 26553136
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Commun. 2016 Sep 26;7:12910
pubmed: 27666519
Nat Rev Genet. 2016 Oct 14;17(11):679-692
pubmed: 27739534
Oncotarget. 2016 Dec 6;7(49):80967-80979
pubmed: 27829232
Am J Cancer Res. 2017 Jul 01;7(7):1566-1576
pubmed: 28744405
Oncogene. 2018 Feb 1;37(5):555-565
pubmed: 28991235
Int J Oncol. 2018 Mar;52(3):743-754
pubmed: 29431182
Oncotarget. 2018 Feb 19;9(18):14580-14596
pubmed: 29581865
Biochem Biophys Res Commun. 2018 Jul 20;502(3):358-363
pubmed: 29807010
Mol Cancer. 2018 Nov 19;17(1):160
pubmed: 30454010
Nature. 1979 Jul 26;280(5720):339-40
pubmed: 460409

Auteurs

Marcel Smid (M)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Saskia M Wilting (SM)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Katharina Uhr (K)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

F Germán Rodríguez-González (FG)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Vanja de Weerd (V)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Wendy J C Prager-Van der Smissen (WJC)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Michelle van der Vlugt-Daane (M)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Anne van Galen (A)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Serena Nik-Zainal (S)

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
East Anglian Medical Genetics Service, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 9NB, United Kingdom.

Adam Butler (A)

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.

Sancha Martin (S)

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.

Helen R Davies (HR)

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.

Johan Staaf (J)

Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.

Marc J van de Vijver (MJ)

Department of Pathology, Academic Medical Center, 1105AZ Amsterdam, the Netherlands.

Andrea L Richardson (AL)

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

Gaëten MacGrogan (G)

Département de Biopathologie, Institut Bergonié, CS 61283 33076 Bordeaux, France.

Roberto Salgado (R)

Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, B-1000 Brussels, Belgium.
Department of Pathology/TCRU GZA, 2610 Antwerp, Belgium.

Gert G G M van den Eynden (GGGM)

Department of Pathology/TCRU GZA, 2610 Antwerp, Belgium.
Molecular Immunology Unit, Jules Bordet Institute, B-1000 Brussels, Belgium.

Colin A Purdie (CA)

Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom.

Alastair M Thompson (AM)

Department of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom.

Carlos Caldas (C)

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, United Kingdom.

Paul N Span (PN)

Department of Radiation Oncology, and Department of Laboratory Medicine, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands.

Fred C G J Sweep (FCGJ)

Department of Laboratory Medicine, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands.

Peter T Simpson (PT)

Centre for Clinical Research, Faculty of Medicine, The University of Queensland, 4029 Brisbane, Australia.

Sunil R Lakhani (SR)

Centre for Clinical Research, Faculty of Medicine, The University of Queensland, 4029 Brisbane, Australia.
Pathology Queensland, The Royal Brisbane and Women's Hospital, 4029 Brisbane, Australia.

Steven Van Laere (S)

Center for Oncological Research, University of Antwerp, 2610 Antwerp, Belgium.

Christine Desmedt (C)

Breast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, B-1000 Brussels, Belgium.

Angelo Paradiso (A)

Istituto Tumori G Paolo II, IRCCS, 70124 Bari, Italy.

Jorunn Eyfjord (J)

Cancer Research Laboratory, Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

Annegien Broeks (A)

The Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Anne Vincent-Salomon (A)

Institut Curie, Department of Pathology and INSERM U934, 75248 Paris Cedex 05, France.

Andrew P Futreal (AP)

Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA.

Stian Knappskog (S)

Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.
Department of Oncology, Haukeland University Hospital, 5021 Bergen, Norway.

Tari King (T)

Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.

Alain Viari (A)

Synergie Lyon Cancer, Centre Léon Bérard, Lyon Cedex 08, France.
Equipe Erable, INRIA Grenoble-Rhône-Alpes, 38330 Montbonnot-Saint Martin, France.

Anne-Lise Børresen-Dale (AL)

Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, 0310 Oslo, Norway.
K.G. Jebsen Centre for Breast Cancer Research, Institute for Clinical Medicine, University of Oslo, 0310 Oslo, Norway.

Hendrik G Stunnenberg (HG)

Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, 6525GA Nijmegen, the Netherlands.

Mike Stratton (M)

Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.

John A Foekens (JA)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Anieta M Sieuwerts (AM)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

John W M Martens (JWM)

Erasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH